Comparison of apolipoprotein-A1 levels between paroxysmal atrial fibrillation patients and healthy subjects

• Main Authors: Tufan Çınar, Veysel Ozan Tanık, Kadir Gürkan
• Format: Article
• Language: English
• Published: Tabriz University of Medical Sciences 2020-06-01
• Series: Journal of Cardiovascular and Thoracic Research
• Subjects: paroxysmal atrial fibrillation; apolipoprotein-a1; inflammation
• Online Access: https://jcvtr.tbzmed.ac.ir/PDF/jcvtr-12-140.pdf
• ISSN: 2008-5117; 2008-6830

Introduction: Studies found that the inflammation plays a key role in the pathogenesis of paroxysmal atrial fibrillation (PAF). It is well-known that apolipoprotein-A1 (Apo-A1) demonstrates antiinflammatory and anti-oxidant properties in a healthy physiological system. In the present study, we aimed to determine whether there is any difference of Apo-A1 levels in patients with PAF and healthy subjects. Methods: In this prospective cohort study, we enrolled a total of 35 PAF patients and 34 comparable healthy participants. Apo-A1 levels were measured from each subject using an immunophelometric method. All enrolled subjects were followed-up for one year during the study period. Results: Serum high-sensitivity C-reactive protein (hs-CRP) levels were statistically higher in PAF patients compared to healthy subjects (1.54±1.99 vs. 1.06±2.01, P= 0.016, respectively). Of note, patients with PAF had lower Apo-A1 levels (1.84±0.74 vs. 2.55±0.44, P= 0.001, respectively). There was no statistical difference between the groups in terms of apolipoprotein-B levels (1.08±0.36 vs. 0.99±0.38, P= 0.339, respectively). We did not find any correlation between Apo-A1 levels and PAF attacks in the study. Conclusion: The main finding of this study was that Apo-A1 levels were significantly lower in PAF patients compared to healthy participants. Based on our results, we considered that Apo-A1 may have a key role in the pathogenesis of PAF.